Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: A Systematic Review and Multilevel Meta-Analysis

Galvain, Thibaut, Hill, Ruaraidh ORCID: 0000-0002-2801-0505, Donegan, Sarah ORCID: 0000-0003-1709-2290, Lisboa, Paulo, Lip, Gregory YH ORCID: 0000-0002-7566-1626 and Czanner, Gabriela (2022) Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: A Systematic Review and Multilevel Meta-Analysis. DRUG SAFETY, 45 (11). pp. 1349-1362.

Text
Galvain_2022_Systematic Review and Multilevel Meta-Analysis.pdf - Author Accepted Manuscript
Download (689kB) | Preview

Official URL: http://dx.doi.org/10.1007/s40264-022-01231-x

Abstract

<h4>Introduction</h4>Atrial fibrillation (AF) is a major cause of stroke. Anticoagulants substantially reduce risk of stroke but are also associated with an increased risk of bleeding. Because of that, many patients do not receive anticoagulants, particularly patients at risk of falls. This systematic review and meta-analysis aims to compare anticoagulant treatment options for the management of atrial fibrillation patients at risk of falls or with a history of falls.<h4>Methods</h4>We conducted a PRISMA systematic review (until March 2022), including studies evaluating safety and efficacy of different anticoagulants (vitamin K antagonist [VKA] versus non-vitamin K antagonist oral anticoagulant [NOAC]). Outcomes were ischemic stroke, major bleeding, intracranial hemorrhage, hemorrhagic stroke, myocardial infarction, gastrointestinal bleeding, cardiovascular and all-cause mortality. A multilevel meta-analysis was conducted adjusting for clustering effects within studies examining more than one effect size.<h4>Results</h4>A total of 919 articles were identified, 848 after removing duplicates. The full text of 155 were screened and 10 articles were retained for final quantitative synthesis. Risk of bias was moderate to serious for the included studies. In meta-analysis, NOACs were associated with superior effectiveness compared with VKA for ischemic stroke/systemic embolism (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.69-0.98; p < 0.05) and safety (HR 0.53, 95% CI 0.40-0.71; p < 0.05) for intracranial hemorrhage. There were no differences in other outcomes.<h4>Conclusion</h4>NOACs were associated with less intracranial hemorrhages and ischemic strokes/systemic embolisms than VKAs in AF patients at risk of falls. These findings suggesting preferred use of NOACs over VKAs have clinical implications for physicians, patients and policy makers.

Item Type:	Article
Uncontrolled Keywords:	Humans, Intracranial Hemorrhages, Atrial Fibrillation, Gastrointestinal Hemorrhage, Anticoagulants, Administration, Oral, Accidental Falls, Stroke, Ischemic Stroke
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Population Health
Depositing User:	Symplectic Admin
Date Deposited:	12 Feb 2024 09:15
Last Modified:	12 Feb 2024 09:15
DOI:	10.1007/s40264-022-01231-x
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3165255